Global Congenital Adrenal Hyperplasia Market Size To Exceed USD 1.055 Billion by 2035 | CAGR of 6.68% : Statistics Report

• As per Spherical Insights & Consulting, The Global Congenital Adrenal Hyperplasia Market Size is expected to Grow from USD 0.518 Billion in 2024 to USD 1.055 Billion by 2035, at a CAGR of 6.68% during the forecast period 2025-2035, owing to the launch of new therapies in the market and the rise in the number of cases.

 

• The leading Congenital Adrenal Hyperplasia Market Companies such as Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, OMass Therapeutics Limited, Eli Lilly and Company, Macleods Pharmaceuticals, BridgeBio Pharma Inc., Applied Therapeutics Inc., Eton Pharmaceuticals Inc., Regenxbio Inc., Sanofi S.A., Millendo Therapeutics Inc., Teva Pharmaceutical Industries, H. Lundbeck A/S, Pfizer Inc., and Others

 

• Congenital Adrenal Hyperplasia Treatment Market: Understanding and Treatment Algorithm:

• Congenital adrenal hyperplasia (CAH) is a group of inherited genetic disorders that affect the adrenal glands, which produce hormones such as cortisol and aldosterone. CAH typically results from enzyme deficiencies, most commonly 21-hydroxylase, leading to hormone imbalances, salt loss, and excess androgen production, causing symptoms such as early puberty and abnormal genital development.

  .

  Congenital Adrenal Hyperplasia Diagnosis:

  Congenital adrenal hyperplasia (CAH) is diagnosed through newborn screening, which measures 17-hydroxyprogesterone levels in the blood. Confirmatory tests include hormone analysis, electrolyte evaluation, and genetic testing to identify specific enzyme deficiencies. Early diagnosis is crucial for prompt treatment to prevent salt-wasting crises, manage hormone levels, and support normal growth and development.

 

• Congenital Adrenal Hyperplasia Treatment

  Treatment for congenital adrenal hyperplasia (CAH) involves lifelong hormone replacement therapy to correct cortisol and aldosterone deficiencies. Glucocorticoids and mineralocorticoids help maintain hormone balance and prevent adrenal crises. In some cases, surgical correction of genital abnormalities is needed. New therapies, including gene therapy and non-steroidal treatments, are under clinical investigation.

 

• Congenital Adrenal Hyperplasia Epidemiology

  The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of Congenital Adrenal Hyperplasia, Gender-specific Diagnosed Incidence of Congenital Adrenal Hyperplasia, Type-specific Diagnosed Incidence of Congenital Adrenal Hyperplasia, Age-specific Diagnosed Incidence of Congenital Adrenal Hyperplasia, Diagnosed Incident Population based on Primary Site of Congenital Adrenal Hyperplasia, and Diagnosed Incident Population based on Histologic Classification of Congenital Adrenal Hyperplasia Tumour in the global market covering North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa from 2024 to 2035.

 

Principal Insights

This section offers a global overview of congenital adrenal hyperplasia epidemiology in major markets worldwide.

 

Country Wise- Congenital Adrenal Hyperplasia Multiforme Epidemiology

• The epidemiology segment provides Congenital Adrenal Hyperplasia prevalence data and findings across key regions worldwide, including North America, Europe (Germany, France, Italy, Spain, and the United Kingdom), Asia-Pacific (including Japan), Latin America, the Middle East, and Africa.

 

Congenital Adrenal Hyperplasia: Recent Developments:

• In September 2024, BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases, announced topline results from its Phase 1/2 open-label ADventure study. The trial investigated BBP-631, the company’s investigational adeno-associated virus (AAV) 5 gene therapy, as a potential treatment for congenital adrenal hyperplasia (CAH), highlighting preliminary safety and efficacy outcomes.

 

Congenital Adrenal Hyperplasia Marketed Drugs:

• Crenessity (crinecerfont): Neurocrine Biosciences

Crenessity is an oral CRF 1 receptor antagonist approved in December 2024. It is used adjunctively with glucocorticoids in adults and children (4 years) with classic CAH to reduce excess adrenocorticotropic hormone (ACTH) and allow glucocorticoid dose reduction

 

• Khindivi (hydrocortisone oral solution): Eton Pharmaceuticals

Khindivi is a ready-to-use oral hydrocortisone liquid designed for pediatric patients with adrenal insufficiency, including CAH. It enables accurate, small-dose adjustments, improving adherence and avoiding the need to split or crush tablets.

 

• Alkindi Sprinkle (hydrocortisone granules): Eton Pharmaceuticals

Alkindi Sprinkle provides hydrocortisone in microgranule form, offering precise dosing for infants and young children with CAH. It supports individualized therapy with child-friendly administration.

 

Congenital Adrenal Hyperplasia: Emerging Therapies

• Crinecerfont: It is a CRF1 receptor antagonist developed to reduce ACTH production and excess androgen levels in CAH patients. It is being studied as a steroid-sparing therapy to improve disease control and reduce the side effects of long-term glucocorticoid use.

 

• Tildacerfont: It is an investigational, oral CRF1 receptor antagonist designed to reduce ACTH and androgen excess in CAH. It is in advanced clinical trials for both adult and pediatric populations, aiming to allow reduced glucocorticoid dosing while maintaining hormonal control.

 

• BBP-631: It is an investigational AAV5 gene therapy targeting the root cause of CAH by delivering a functional CYP21A2 gene. It aims to restore endogenous cortisol production and potentially eliminate the need for lifelong steroid treatment.

 

• Atumelnant: It is a selective ACTH receptor (MC2R) antagonist being developed to directly block ACTH signaling. It aims to reduce adrenal androgen production in CAH patients and improve control without increasing glucocorticoid exposure.

 

Congenital Adrenal Hyperplasia Market Outlook

• The congenital adrenal hyperplasia (CAH) market encompasses the development, manufacturing, and sales of therapies and diagnostics for CAH, a genetic disorder affecting adrenal hormone production. The market includes hormone replacement treatments, gene therapies, and diagnostic tools aimed at managing and improving patient outcomes.

 

• Key drivers of the Congenital Adrenal Hyperplasia (CAH) market include rising awareness and early diagnosis through newborn screening, increasing prevalence of CAH, advancements in gene and non-steroidal therapies, growing demand for personalized treatments, and expanding healthcare infrastructure globally supporting better patient management.

 

• Opportunities in the market arise from ongoing research in gene therapies, development of novel non-steroidal treatments, expanding pediatric treatment options, unmet needs in low- and middle-income countries, and potential collaborations between biotech firms to accelerate innovative drug development.

 

• Global government initiatives focus on newborn screening programs, funding research for advanced therapies, improving healthcare access, and raising awareness to enable early diagnosis and effective management, ultimately reducing disease burden worldwide.

 

• Limited awareness, high treatment costs, and challenges in developing effective long-term therapies hinder growth in the congenital adrenal hyperplasia market.

 

• The market is projected to grow due to increasing diagnosis rates, advances in treatment options, and rising demand for personalized therapies.

 

Congenital Adrenal Hyperplasia Market Segmentation

By Type:

• Classic CAH
• Non-Classic CAH

 

 

The Classic CAH segment dominates the market share due to its severe symptoms requiring early diagnosis and lifelong treatment. This increases demand for hormone replacement therapies and advanced treatments, driving higher healthcare utilization and market growth compared to the milder, often undiagnosed Non-Classic CAH segment.

 

By Treatment & Diagnosis:

• Diagnosis
• Treatment

 

 

The Diagnosis segment holds the largest share in the Congenital Adrenal Hyperplasia market due to widespread newborn screening programs, early detection efforts, and advancements in diagnostic tools. High testing volumes, mandatory screening in many regions, and increased awareness contribute significantly to its dominance over the treatment segment in market value.

 

Regional Segment Analysis of the Congenital Adrenal Hyperplasia Market

North America holds the largest share of the congenital adrenal hyperplasia (CAH) market due to well-established healthcare infrastructure, widespread newborn screening programs, high awareness of CAH, and easy access to advanced treatments. The presence of leading pharmaceutical companies and ongoing research further boosts market growth. Additionally, government support and reimbursement policies facilitate patient access to novel therapies and diagnostics, strengthening North America’s dominance.

 

The Asia-Pacific region is the fastest-growing market for CAH, driven by increasing healthcare investments, expanding newborn screening initiatives, and rising awareness about genetic disorders. Growing populations, improving healthcare infrastructure in emerging economies, and rising adoption of advanced treatment options contribute to rapid growth. Additionally, increasing collaborations between local and global pharmaceutical companies are accelerating drug development and market penetration in this region.

 

Congenital Adrenal Hyperplasia Market Key Companies

• Thermo Fisher Scientific Inc.
• Takeda Pharmaceutical Company Limited
• OMass Therapeutics Limited
• Eli Lilly and Company
• Macleods Pharmaceuticals
• BridgeBio Pharma Inc.
• Applied Therapeutics Inc.
• Eton Pharmaceuticals Inc.
• Regenxbio Inc.
• Sanofi S.A.
• Millendo Therapeutics Inc.
• Teva Pharmaceutical Industries
• H. Lundbeck A/S
• Pfizer Inc.
• Others

 

Congenital Adrenal Hyperplasia Therapeutics Market Report Scope

• The Congenital Adrenal Hyperplasia therapeutics market report provides a detailed overview, covering its causes, symptoms, disease progression, and existing treatment options.
• Detailed insights into Congenital Adrenal Hyperplasia’s epidemiology and therapeutic approaches are included.
• Additionally, a comprehensive review of existing and emerging Congenital Adrenal Hyperplasia therapies is provided, including an evaluation of new treatments expected to influence the current Congenital Adrenal Hyperplasia treatment market landscape.
• The report includes a detailed review of the Congenital Adrenal Hyperplasia therapeutics market, both historical and forecasted, highlighting the global drug reach.
• The Patient-Based Congenital Adrenal Hyperplasia Market Forecasting report offers valuable insights into trends shaping the global Congenital Adrenal Hyperplasia market, helping to develop effective business strategies.

 

Congenital Adrenal Hyperplasia Treatment Market Report Insights

• Forecasting Market Trends Based on Patient Data and Disease Rates
• Congenital Adrenal Hyperplasia Therapeutic Approaches in Congenital Adrenal Hyperplasia
• Review Of Drugs in Development for Congenital Adrenal Hyperplasia
• Market, Growth, and Trends in Congenital Adrenal Hyperplasia
• Market Opportunities in Congenital Adrenal Hyperplasia Treatment
• Effects Of Future Therapies on Congenital Adrenal Hyperplasia Treatment.

 

Congenital Adrenal Hyperplasia Treatment Market Report Key Strengths

• 15 Years Congenital Adrenal Hyperplasia Market Forecast
• Global Coverage
• Congenital Adrenal Hyperplasia Epidemiology Segmentation
• Key Cross Competition

 

Congenital Adrenal Hyperplasia Treatment Market Report Assessment

• Present Practices in the Congenital Adrenal Hyperplasia Treatment Market
• Review of Investigational Congenital Adrenal Hyperplasia Drugs
• Attractiveness of the Congenital Adrenal Hyperplasia Drug Market
• Congenital Adrenal Hyperplasia Market Drivers
• Congenital Adrenal Hyperplasia Market Barriers
• SWOT
• Attribute Analysis

 

Market Segment

This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the congenital adrenal hyperplasia market based on the below-mentioned segments:

 

Global Congenital Adrenal Hyperplasia Market, By Type

• Classic CAH
• Non-Classic CAH

 

Global Congenital Adrenal Hyperplasia Market, By Treatment & Diagnosis 

• Diagnosis
• Treatment

 

Global Congenital Adrenal Hyperplasia Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa